What is the bleeding risk of Kisunla (donanemab) in patients taking Eliquis (apixaban)?

Bleeding Risk of Kisunla (Donanemab) in Patients Taking Eliquis (Apixaban)

The concurrent use of Kisunla with Eliquis significantly increases the risk of intracerebral hemorrhage, and this combination requires careful risk-benefit assessment with enhanced monitoring for ARIA-related bleeding complications.

Understanding the Core Risk: ARIA and Bleeding

Kisunla (donanemab) carries a specific warning about Amyloid Related Imaging Abnormalities (ARIA), which includes both brain swelling (ARIA-E) and bleeding (ARIA-H). The FDA label explicitly states that "use of antithrombotic or thrombolytic medications while taking KISUNLA may increase the risk of bleeding in the brain" 1. This is not a theoretical concern—intracerebral hemorrhages greater than 1 cm in diameter have been reported in patients taking Kisunla.

Key Risk Factors for ARIA-Related Bleeding:

• ApoE ε4 genotype status: Homozygotes have the highest risk (57.1% ARIA-E incidence), followed by heterozygotes (25.0%), with noncarriers having the lowest risk (15.6%) 1
• Concurrent anticoagulation: The FDA label specifically warns about increased bleeding risk with antithrombotic medications
• Age: Most Kisunla patients are elderly (mean age 73-77 years in trials), which overlaps with typical apixaban users

Apixaban's Bleeding Profile

Apixaban itself carries bleeding risks that are well-characterized:

• Major bleeding rates: 2.13% per year in the ARISTOTLE trial 2, 3
• Intracranial hemorrhage: Significantly lower than warfarin but still present
• Gastrointestinal bleeding: Similar to warfarin 4, 2

In elderly patients with renal impairment—common in Alzheimer's disease populations—apixaban's bleeding risk increases. Patients with severe chronic kidney disease (stage 4/5) on apixaban 5 mg had higher bleeding rates (4.9 events per 100 person-years) compared to the 2.5 mg dose 5.

Clinical Decision Algorithm

Step 1: Assess Absolute Necessity of Both Medications

• Is anticoagulation absolutely required? Consider the patient's CHA₂DS₂-VASc score and bleeding risk (HAS-BLED score)
• Is Kisunla appropriate? Evaluate if the patient meets criteria for early symptomatic Alzheimer's disease treatment

Step 2: Genetic Testing and Risk Stratification

Before initiating Kisunla, ApoE ε4 testing is essential 1:

• Homozygotes: Highest ARIA risk—consider alternative Alzheimer's treatments if on anticoagulation
• Heterozygotes: Moderate risk—proceed with extreme caution and enhanced monitoring
• Noncarriers: Lower but still elevated risk with anticoagulation

Step 3: Optimize Anticoagulation Strategy

If both medications are deemed necessary:

Apixaban dosing considerations:

• Use the lowest effective dose based on FDA criteria (2.5 mg twice daily if ≥2 of: age ≥80 years, weight ≤60 kg, serum creatinine ≥1.5 mg/dL) 2, 3
• In severe CKD, the 2.5 mg dose has lower bleeding risk without increased thrombotic events 5
• Avoid dose escalation beyond what's indicated

Avoid additional bleeding risk factors:

• Do not combine with antiplatelet agents (aspirin, P2Y12 inhibitors) unless absolutely necessary—these significantly increase bleeding risk 6, 7, 8
• Avoid interacting medications: Amiodarone increases apixaban-related bleeding (HR 1.44) 7; systemic fluconazole increases bleeding risk with apixaban (OR 3.5) 9

Step 4: Enhanced Monitoring Protocol

MRI surveillance for ARIA:

• Baseline MRI before Kisunla initiation
• More frequent MRI monitoring than standard Kisunla protocol (typically before doses 2,3,4, and 7, then every 4 doses) 1
• Immediate MRI if any neurological symptoms develop (headache, confusion, vision changes, weakness, seizure)

Clinical monitoring:

• Assess for bleeding symptoms at every visit
• Monitor renal function closely (apixaban accumulation in AKI increases bleeding risk) 10
• Educate patients to report any bleeding or neurological symptoms immediately

Step 5: Management of Bleeding Events

If ARIA with hemorrhage occurs:

• Immediately discontinue Kisunla 1
• Consider temporary interruption of apixaban (consult with neurology and cardiology)
• For life-threatening bleeding, andexanet alfa is available for apixaban reversal (Class IIa recommendation) 11, 12
• Resume anticoagulation only after careful risk-benefit reassessment and resolution of ARIA

Critical Caveats

1. No direct clinical trial data exists for the combination of Kisunla and apixaban—this recommendation is based on mechanistic understanding and FDA warnings

2. ARIA symptoms can mimic ischemic stroke 1—this creates diagnostic complexity in anticoagulated patients presenting with neurological symptoms

3. Patients should carry information that they are on Kisunla to inform emergency providers 1

4. The bleeding risk is cumulative—elderly patients with multiple risk factors (age, renal impairment, anticoagulation, ARIA risk) face substantially elevated bleeding risk

Alternative Considerations

If the bleeding risk appears prohibitive:

• Consider alternative anticoagulants with shorter half-lives for easier management (though all carry similar warnings)
• Evaluate left atrial appendage closure for stroke prevention in appropriate candidates to eliminate need for anticoagulation 13
• Consider delaying Kisunla until anticoagulation can be safely discontinued (if clinically appropriate)
• Discuss alternative Alzheimer's treatments with lower bleeding risk profiles

The combination of Kisunla and apixaban should only be used when both medications are absolutely necessary, with full informed consent about increased bleeding risks, mandatory ApoE ε4 testing, optimized apixaban dosing, elimination of additional bleeding risk factors, and enhanced monitoring protocols in place.